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Abstract
Purpose Despite national and international guideline recommendations, few studies have been conducted to estimate the 
impact of colonoscopy screening on long-term colorectal cancer incidence. Aim of this study was to determine the long-term 
impact of a full colonoscopy with polypectomy on colorectal cancer incidence in a large screening population.
Methods In this prospective observational cohort study, a total of 10,947 colonoscopy screening participants from within the 
scope of the Munich Cancer Registry were consecutively recruited from participating gastroenterology practices and their 
subsequent colorectal cancer incidence assessed. Predictive factors associated with colorectal cancer were also evaluated in 
univariate and multivariate analyses.
Results After a median follow-up of 14.24 years (95% CI [14.21–14.25]), 93 colorectal cancer cases were observed. This 
is equivalent to a truncated age-standardized rate of 69.0 (95% CI [43.3–94.7]) for male and 43.4 (95% CI [29.4–57.5]) for 
female participants (≥ 50 years at colonoscopy). The ratio of this observed to the expected rate from cancer registry data 
showed a 67% decrease in colorectal cancer incidence in the male and 65% in the female participants (p < 0.0001). In multi-
variate analysis of screening patients, age at screening (p < 0.0001) was the main predictive factor for colorectal cancer. In the 
subgroup with positive polyp findings, age (p < 0.0001) and the polyp size (p = 0.0002) were associated with colorectal cancer.
Conclusion These results underline the significance of a full colonoscopy screening combined with polypectomy in reducing 
the total disease burden of colorectal cancer.
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Introduction
Although colorectal cancer (CRC) rates have declined in the 
last decade, it remains among the most frequently diagnosed 
cancers. Therefore, screening programs with high patient 
participation rates are essential in decreasing the overall dis-
ease burden and mortality from CRC through early detec-
tion of neoplasms or removal of precursor lesions. A large 
number of countries have recently adopted colonoscopy for 
the general population as the primary screening instrument 
for CRC. This screening procedure has consistently shown 
a high sensitivity and also provides a simultaneous cura-
tive polyp removal (Lieberman 2009; Issa and Noureddine 
2017). In Germany, screening colonoscopy within a quality 
assurance program has been offered since 2002. However, 
overall participation and adherence remains relatively low at 
58.5% (Starker et al. 2018). An organized screening began 
in 2019 with invitations for subjects aged ≥ 55 years (no 
upper age limit) and with the option of a second screening 
colonoscopy ≥ 10 years later if no polyps are found. Persons 
with increased risk factors such as a familial history of CRC 
or previous history of inflammatory bowel disease may be 
screened earlier (Niedermaier et al. 2018; AWMF 2019).
Studies detailing the impact of colonoscopy on can-
cer incidence or mortality have mainly been designed as 
observational cohort or case–control studies because of 
the already proven efficacy of sigmoidoscopy in reducing 
cancer incidence. Most published studies have reported a 
drop in both incidence and mortality mainly attributed to 
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polypectomy, most notably the National Polyp Study which 
reported a 76% decrease in CRC incidence (Winawer et al. 
1993; Thiis-Evensen et al. 1999; Kaminski et al. 2010; Zau-
ber et al. 2012). Two large RCTs by Atkin et al. and the 
PLCO by Schoen et al. using sigmoidoscopy, limited to an 
examination of the distal colon, reported a CRC incidence 
reduction of 21% and 23% compared to a control group not 
screened (Atkin et al. 2010; Schoen et al. 2012). Compari-
sons to non-invasive screening tests such as the fecal immu-
nochemical test showed an increase in patient participation, 
while the detection rate of precursor lesions was lower 
(Quintero et al. 2012).
The objective of the present study was therefore to deter-
mine the impact of a colonoscopy screening examination 
on the colorectal cancer incidence of a regional cohort of 
participants within the scope of the Munich Cancer Registry 
(MCR) in Bavaria, Germany.
Methods
Study participants
A closed cohort of participants was included in a prospective 
observational study following a singular colonoscopy exam 
with or without polypectomy. The study design was obser-
vational and did not include any procedures for blinding 
or randomization. Only a single colonoscopy examination 
was documented in the study, and information on additional 
examinations, as recommended in current guidelines, was 
not available. In addition, information on the indication of 
the colonoscopy was not documented and may have been 
both for purely screening purposes and due to apparent 
symptoms. Participants were eligible for the study if they 
underwent a colonoscopy examination at one of the 48 par-
ticipating gastroenterology practices within the scope of 
the MCR (Supplemtary Table 2). The catchment area of the 
MCR currently encompasses a population of approximately 
4.9 million inhabitants Munich Cancer Registry (MCR) 
(2019). An informed consent was obtained from all study 
participants prior to the examination. The study conduct 
followed the tenets of the Declaration of Helsinki. For each 
participant, baseline demographic and colonoscopy data 
were collected, namely all excised polyps were morpho-
logically categorized as adenomatous, non-adenomatous, or 
mixed type. Maximum size of the polyp diameter (measured 
using a ruler by the examining pathologists) and quantity 
were also recorded.
By follow-up data linkage with MCR data, subsequent or 
prior cancer diagnoses were merged to the dataset of par-
ticipants, with a final data retrieval conducted in July 2020 
and final life status follow-up in Mai 2019. A total of 11,842 
participants were recruited for the study between January 
2005 and September 2009 after a quality assurance pro-
gram was established. Excluding participants with missing 
identifying data (n = 292), duplicate screening data (n = 46), 
prior colorectal tumor diagnoses (n = 113), or moving out of 
the MCR catchment area (n = 444) resulted in a final study 
cohort of 10,947 participants. Benign (n = 76) diagnoses 
were excluded and 58 colorectal cancer diagnoses during the 
procedure or within the first 30 days following the screening 
date were considered separately. A total of 93 CRC cases 
were observed after a median follow-up of 14.24 years. Fig-
ure 1 shows the participant flowchart.
Statistical analysis
Assuming a power of 80% and a type I error of 5%, the 
sample size calculation was based on the estimation that 
0.16% of the population at 60 years old would develop CRC. 
Considering a 5% loss to follow-up quota and 75% negative 
colonoscopy findings, a required sample size of 8000 par-
ticipants was determined.
The primary outcome of this study was to determine the 
impact of the colonoscopy examination on colorectal cancer 
incidence during the follow-up observation period. Cancer 
incidence in the study cohort was determined using the per-
son-years at risk per sex and 5-year age groups, adjusted to 
BRD standard to obtain the ASR (age-standardized rate), as 
well as the truncated age-standardized rate in the designated 
screening population (TASR, age > 50 years at screening). 
Although the recommended screening age is currently set at 
55 in women the cut-off age 50 years was used for both sexes 
due to the ongoing discussion on a general lower age limit 
for the initial colonoscopy screening (Vuik et al. 2019). This 
was performed for the screening study cohort and for a pop-
ulation-based cohort from the MCR during the same time 
period. The standardized incidence ratios for incidence were 
used to compare rates. Poisson distribution was assumed for 
the number of CRC cases and the 95% confidence interval 
was calculated accordingly. The cumulative risk was calcu-
lated according to Bray et al. (2017).
Time to CRC data for the primary outcome was calcu-
lated from the date of the screening procedure (n = 10,947) 
until the first colorectal cancer diagnosis. To account for 
the competing risk of death by any cause, a cumulative 
incidence analysis was used to calculate the time to CRC. 
Differences among subgroups were assessed using Fine’s 
Gray Test for Equality of Cumulative Incidence Functions 
(Kalbfleisch and Prentice 2011). The subgroup of partici-
pants considered presumably healthy without any recorded 
tumor diagnosis (CRC or other cancer type) were not con-
sistently monitored and no follow-up data were available. 
Therefore, the expected survival time was estimated using 
national life tables.
Journal of Cancer Research and Clinical Oncology 
1 3
Overall survival was determined for participants with 
prevalent and incidental CRC. Overall survival (OS) from 
date of CRC until date of death was estimated using the 
Kaplan–Meier method and tested using the log-rank test.
For a graphical comparison of OS, five age- and sex-
matched random samples were drawn from the MCR pop-
ulation during the same time period: four samples cor-
responding to the sample size of incidental CRC cases 
(samples 1–3), as well as one larger sample (Max cohort 
MCR—follow-up). One sample corresponds to the preva-
lent cases (Max cohort MCR—screening).
A multivariate analysis of independent predictive fac-
tors were assessed using the Fine‐Gray sub-distribution 
hazard model (Fine and Gray 1999). The hazard ratio and 
95% CIs are given in the results. Baseline demographics 
and colonoscopy results were entered simultaneously as 
independent predictive variables for a multivariate analy-
ses of CRC risk. Similar to the calculation of CRC inci-
dence, only patients > 50 years at screening were included.
Pearson’s chi-square was used to compare categorical, 
and Student’s t test for numerical variables between indi-
vidual subgroups. The Pearson’s correlation coefficient 
was used to determine bivariate correlation of continuous 
variables. Percentages for individual subgroups consider 
available data only, and missing values are given in rela-
tion to the underlying cohort or subgroup for the respective 
category.
For all analyses, a two-sided p value of 0.05 or less was 
considered statistically significant. IBM SPSS Statistics ver-
sion 25 and Statistical Analysis Software version 9.4 (SAS 
Institute, Cary, NC) were used for data analysis.
Results
Screening demographics
Baseline demographics of the screening cohort are shown in 
Table 1. The study participants had a median age of 62 years 
at screening (range 15–97) and therefore within the recom-
mended age range for colonoscopy screening.
Colonoscopy
In the majority of participants, no polyps were found (62.3%, 
Table 1). In the subgroup with manifest polyps, the histology 
was mainly adenomatous (61.4%), 28.4% were classified as 
non-adenomatous, and the remaining polyps (10.1%) were 
categorized as having mixed adenomatous/non-adenomatous 
histology. The median number of polyps varied between 
one in the adenomatous (range 1–101) and non-adenom-
atous (range 1–100) groups, and two in the mixed group 
(range 1–20). The adenomatous and mixed polyps both had 
a median maximum diameter of 5 mm (adenomatous, range 
Fig. 1  Study participant flowchart: CRC, colorectal cancer. Percentages are derived from the total screening cohort. *Indicates multiple cancer 
diagnoses counted separately for each time point. Ø, without
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Table 1  Baseline cohort demographics and screening characteristics, overall, and for male and female subgroups individually
Percentages for individual subgroups consider available data only, and missing values are given in relation to the underlying cohort or subgroup 
for the respective category
a The maximum value from either adenomatous or non-adenomatous was selected. p values calculated with χ2 test to compare male and female 
subgroups
N (%) Person-years CRC cases (% of 
screening cohort)







Total 10 947 150,714.1 93 (0.9) 61.7
Sex
 Male 4851 (43.3) 65,572.8 48 (1.0) 73.2
 Female 6096 (55.7) 85,141.3 45 (0.7) 52.9
Age groups [years at screening]
 < 50 1240 (11.3) 17,457.8 1 (0.1) 5.7 538 (11.1) 702 (11.5)  < 0.0001
 50–59 2964 (27.1) 42,163.5 13 (0.4) 30.8 1176 (24.2) 1788 (29.3)
 60–69 4924 (45.0) 69,752.0 42 (0.8) 60.2 2260 (46.6) 2664 (43.7)
 70–79 1623 (14.8) 19,952.2 35 (2.2) 175.4 785 (16.2) 838 (13.8)
 ≥ 80 196 (1.8) 1388.6 2 (1.0) 144.0 92 (1.9) 104 (1.7)
Colonoscopy result
 No finding 6820 (62.3) 94,554.6 46 (0.6) 48.7 2267 (55.0) 4153 (68.1)  < 0.0001
 Polyps found 4127 (37.7) 56,159.5 47 (1.1) 83.7 2184 (45.0) 1943 (31.9)
 Polyp histology
 Adenomatous 2536 (61.4) 34,352.8 30 (1.2) 87.3 1386 (63.5) 1150 (59.2)  < 0.0001
 Non-adenomatous 1173 (28.4) 16,193.6 9 (0.8) 55.6 555 (25.4) 618 (31.8)
 Mixed adenomatous/
non-adenomatous
418 (10.1) 5613.2 8 (1.9) 142.5 243 (11.1) 175 (9.0)
Number of polyps [n]
 Adenomatous
  1–2 1950 (78.8) 26,625.7 17 (0.9) 63.8 1023 (75.7) 927 (82.6)  < 0.0001
  3–4 407 (16.4) 5420.1 13 (3.2) 239.8 246 (18.2) 161 (14.3)
  ≥ 5 118 (4.8) 1557.8 0 – 83 (6.1) 35 (3.1)
  Missing 61 (2.4) – 34 27
 Non-adenomatous
  1–2 1007 (87.7) 13,940.5 8 (0.8) 57.4 466 (86.5) 541 (88.8) 0.457
  3–4 96 (8.4) 1326.0 0 – 49 (9.1) 47 (7.72)
  ≥ 5 45 (3.9) 610.4 0 – 24 (4.5) 21 (3.45)
  Missing 25 (2.1) – 16 9
 Mixed adenomatous/non-adenomatousa
  1–2 298 (71.3) 3957.6 8 (2.7) 202.1 173 (71.2) 125 (71.4) 0.564
  3–4 90 (21.5) 1249.6 0 – 50 (20.6) 40 (22.9)
  ≥ 5 30 (7.2) 406.0 0 – 20 (8.2) 10 (5.7)
Largest polyp diameter [mm]
 Adenomatous
  < 5 835 (34.2) 11,438.7 5 (0.6) 43.7 447 (33.5) 388 (35.1) 0.129
  5–10 1202 (49.2) 16,426.8 9 (0.7) 54.8 649 (48.6) 553 (50.0)
  > 10 405 (16.6) 5203.4 15 (3.7) 288.3 240 (18.0) 165 (14.9)
  Missing 94 (3.7) – – – 50 44
 Non-adenomatous
  < 5 659 (58.4) 9111.2 8 (1.2) 87.8 317 (60.3) 342 (56.8) 0.365
  5–10 430 (38.1) 5945.8 1 (0.2) 16.8 194 (36.9) 236 (39.2)
  > 10 39 (3.5) 545.0 0 – 15 (2.8) 24 (4.0)
  Missing 45 (3.8) – – – 29 16
 Mixed adenomatous/non-adenomatousa
  < 5 145 (35.6) 1971.7 3 (2.1) 151.2 81 (34.2) 64 (37.4) 0.756
  5–10 209 (51.4) 2758.4 3 (1.4) 108.8 125 (52.7) 84 (49.1)
  > 10 54 (13.0) 754.0 1 (1.8) 132.6 31 (13.1) 23 (13.5)
  Missing 10 (6.0) – – – 6 4
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1–200 mm; mixed, range 1–80 mm), followed the non-ade-
nomatous subgroup (Median = 4 mm, range 1–40 mm). Age 
at screening was correlated to size (p = 0.0175) but not to the 
number of polyps found (p = 0.4092). The number of polyps 
and maximum size were also correlated (p < 0.0001).
Sex‑based differences
Slightly more female (55.7%) than male participants took 
part in the study (p < 0.0001). This sex-based discrepancy 
was especially evident for participants between 50 and 
59 years (female 60.3% vs. 39.7%), but remained consist-
ent over all other age groups, as well. Female participants 
were also on average 1 year younger (median 62.0 vs. 63.0). 
Sex-based differences were also observed in the colonos-
copy findings with fewer polyps found in female participants 
compared to male participants (p < 0.0001). Female partici-
pants also presented more frequently with non-adenomatous 
(31.8% vs. 25.4%) compared to their male counterparts, 
while overall size and number was similar. Female partici-
pants with adenomatous polyp histology had fewer polyps 
in total (p < 0.0001).
CRC prevalence
In total, 151 participants were diagnosed with colorectal 
cancer, 58 during the screening colonoscopy. These 58 cases 
are equivalent to three-times the expected incidence in this 
cohort. These participants were a median 68 years (range 
43.0–89.0) at diagnosis and predominately male (65.5%) 
(Table 2). Tumors were mainly found in the left colon 
(79.3%), with an intermediate grade (77.6%) and adenocar-
cinoma histology (93.1%) characterizing the tumor biology. 
A total of 52.7% of cases presented in UICC stages I or II.
CRC incidence
A total of 93 CRCs occurred in the follow-up observation 
period (Table 2). Cases were observed in men (51.6%) and 
in older participants irrespective of sex (overall median age 
at diagnosis = 75, range [52–92]). The majority of tumors 
were located on the right side of the colon (55.9%) and pre-
sented in the more favorable UICC stages I or II (57.0%). 
The tumor histopathology was primarily intermediate grade 
adenocarcinoma. The CRC diagnosis represented the first 
tumor diagnosis for most participants (77.4%), 19.4% and 
3.2% of participants had one or two previous cancer diagno-
ses not located in the colon. The events observed in the study 
screening participants resulted in an ASR of 24.1 (95%CI 
[15.3–33.0]) for male and 14.8 (95%CI [10.1–19.6]) for 
female participants (Supplementary Table 1). The expected 
values were derived from the equivalent MCR data and 
yielded an ASR of 73.4 (95%CI [72.2–74.6]) for the male 
and 45.2 (95%CI [44.3–46.0]) for the female population. The 
standardized incidence ratio between both (SIR) was 0.33 
for men (95%CI [0.27–0.40]), and 0.33 for women (95%CI 
[0.28–0.39]; p < 0.0001).
Limiting the comparison to the population of interest in 
a truncated analysis (screening age > 50 years) resulted in 
a truncated age-standardized rate (TASR) of 69.0 (95%CI 
[43.3–94.7]) in male and 43.4 (95%CI [29.4–57.5]) in female 
participants. The respective TASR in the MCR population 
was 208.4 (95%CI [204.9–211.8]) in the male and 124.1 
(95%CI [121.8–126.5]) in the female population. A com-
parison of both TASR rates showed a ratio of 0.33 (95%CI 
[0.27–0.40]) and 0.35 (95%CI [0.29–0.42]), respectively, for 
men and women (p < 0.0001, Supplementary Table 1).
This number of recorded events was equivalent to a 
cumulative incidence of 0.3 (95%CI [0.2–0.5]) for men and 
0.2 (95%CI [0.1–0.4]) for women after 5 years of follow-
up, which is equivalent to, respectively, 32% of the total 
observed CRC cases. The overall cumulative risk for CRC 
came to 4.6% for men and 2.3% for women in the study 
cohort compared to a cumulative risk of 10.2% and 6.8% in 
the comparison populations.
CRC incidence by sex and polyps
The median follow-up time was 14.24  years (95%CI 
[14.21–14.25] years). Median time from screening to diag-
nosis was 6.4 years in men (range 0.2–13.7 years) and 
7.9 years in women (range 0.1–13.5 years, Fig. 2a). Out 
of all cases, a CRC diagnosis was made within the first 
6 months after the study colonoscopy in five men and one 
woman. Figure 2a illustrates the cumulative CRC incidence 
over the entire observation period stratified by sex. Although 
there were slightly more events observed for male partici-
pants, this difference was not significant (p = 0.1473). The 
cumulative incidence according to age did show a significant 
difference; here, older participants (> 70 years at screening) 
showed the highest incidence of CRC (p < 0.0001). Polypec-
tomy results (p = 0.0084), as well as the number (p = 0.0137) 
and maximum diameter of removed polyps (p < 0.0001) 
likewise influenced the cumulative CRC incidence. A risk 
for CRC remained even in patients without any detected 
polyps. Polyps with an adenomatous component, number-
ing 3–4 polyps, and a maximum diameter of ≥ 10 mm were 
most highly associated with a subsequent CRC diagnosis 
(Fig. 3a–c).
Predictive factors and prognosis
In a multivariate fine-gray model of the factors sex 
(p = 0.4521), polyp finding (p = 0.0988), only age at diag-
nosis remained as a significant independent predictor for 
CRC (p < 0.0001, Table 3). Focusing on the participants with 
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Table 2  Colorectal cancer 
during screening and follow-up 
period
Percentages for individual subgroups consider available data only, and missing values are given in relation 
to the underlying cohort or subgroup for the respective category
a UICC stadium according to TNM classification version 8
b Last date of life status follow-up Mai, 2019









Participants with CRC 58 38 20 93 48 45
Age [years at diagnosis]
 40–44 4 (6.9) 2 (5.3) 2 (10.0) 0 0 0
 45–49 1 (1.7) 1 (2.6) 0 0 0 0
 50–54 2 (3.4) 1 (2.6) 1 (5.0) 1 (1.1) 1 (2.1) 0
 55–59 3 (5.2) 2 (5.3) 1 (5.0) 1 (1.1) 0 1 (2.2)
 60–64 9 (15.5) 5 (13.2) 4 (20.0) 10 (10.8) 6 (12.5) 4 (8.9)
 65–69 13 (22.4) 9 (23.7) 4 (20.0) 12 (12.9) 5 (10.4) 7 (15.6)
 70–74 11 (19.0) 8 (21.0) 3 (15.0) 20 (21.5) 11 (22.9) 9 (20.0)
 75–79 9 (15.5) 5 (13.2) 4 (20.0) 26 (28.0) 11 (22.9) 15 (33.3)
 80–84 4 (6.9) 3 (7.9) 1 (5.0) 14 (15.1) 9 (18.8) 5 (11.1)
 ≥ 85 2 (3.4) 2 (5.3) 0 9 (9.7) 5 (10.4) 4 (8.9)
Side
 Left 46 (79.3) 32 (84.2) 14 (70.0) 41 (44.1) 24 (50.0) 17 (37.8)
 Right 12 (20.7) 6 (15.8) 6 (30.0) 52 (55.9) 24 (50.0) 28 (62.2)
Localization
 Colon 30 (51.7) 17 (44.7) 13 (65.0) 67 (72.0) 37 (77.1) 30 (66.7)
 Rectosigmoid junction 10 (17.2) 7 (18.4) 3 (15.0) 5 (5.4) 3 (6.2) 2 (4.4)
 Rectum 18 (31.0) 14 (36.8) 4 (20.0) 21 (22.6) 8 (16.7) 13 (28.9)
UICC  stadiuma
 0 0 0 0 2 (2.2) 2 (4.8) 0
 I 21 (36.2) 10 (26.3) 11 (55.0) 24 (25.8) 13 (31.0) 11 (27.5)
 II 8 (13.8) 6 (15.8) 2 (10.0) 29 (31.2) 14 (33.3) 15 (37.5)
 III 19 (32.7) 15 (39.5) 4 (20.0) 18 (19.4) 8 (19.0) 10 (25.0)
 IV 7 (12.1) 6 (15.8) 1 (5.0) 9 (9.7) 5 (11.9) 4 (10.0)
 Missing 3 (5.2) 1 (2.6) 2 (10.0) 11 (11.8) 6 5
Grading
 G1 1 (1.7) 1 (2.6) 0 8 (8.6) 4 (10.3) 4 (9.5)
 G2 45 (77.6) 31 (81.6) 14 (70.0) 56 (60.2) 30 (76.9) 26 (61.9)
 G3 9 (15.5) 6 (15.8) 3 (15.0) 17 (18.3) 5 (12.8) 12 (28.6)
 Missing 3 (5.2) 0 3 (15.0) 12 (12.9) 9 3
Histology
 Adenocarcinoma 54 (93.1) 36 (94.7) 18 (90.0) 64 (68.8) 32 (76.2) 32 (76.2)
 Mucinous carcinoma 2 (3.4) 2 (5.3) 0 7 (7.5) 4 (9.5) 3 (7.1)
 Carcinoma in situ 2 (3.4) 0 2 (10.0) 6 (6.5) 4 (9.5) 2 (4.8)
 Carcinoid tumor 0 0 0 4 (4.3) 2 (4.8) 2 (4.8)
 Signet ring cell carcinoma 0 0 0 2 (2.2) 0 2 (4.8)
 GIST 0 0 0 1 (1.1) 0 1 (2.4)
 Missing 0 0 0 9 (9.7) 6 3
CRC  mortalityb
 Alive 32 (55.2) 15 (39.5) 17 (85.0) 65 (69.9) 33 (68.8) 32 (71.1)
 Deceased 26 (44.8) 23 (60.5) 3 (15.0) 28 (30.1) 15 (31.3) 13 (28.9)
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polyps in a model with sex, age, and polyp characteristics 
summarized in Table 3, again age was an independent pre-
dictor of CRC (p < 0.0001), as well as the maximum polyp 
diameter (p = 0.0002). Polyp histology (p = 0.5200), sex 
(p = 0.6701), and the number of polyps (p = 0.1030) were 
not significant in the model.
At the last date of follow-up 69.9% of participants with 
CRC diagnosis were still alive. Comparison of overall sur-
vival after CRC according to sex was not significant, most 
likely due to the small sample size and large data variance 
(Fig. 4a p = 0.9821). In Fig. 4b, the overall survival of the 
MCR population from the same time period is shown. Fig-
ure 4c compares the OS of the study cohort (incidental 
and prevalent cases) to that of five representative random 
samples from the MCR population data. The overall 3-year 
survival of the incidental CRC cases was 80.2% and the 
5-year survival rate was 75.9%, compared to 66.3/55.8% in 
the MCR population. Median survival time was 7.68 years 
(95% CI [6.25–10.67]), 6.76 (95%CI [4.96–9.20]) in men 
and 5.90 years in women, respectively (95%CI [3.71–7.92]; 
Fig. 2a).
Discussion
The study detailed above aimed to examine the associa-
tion between colonoscopy screening and subsequent CRC 
incidence and prognosis in a cohort of participants from 
Bavaria, Germany. Although a broad range of age groups 
were included in the study data, the final analysis focused 
Fig. 2  a, b Cumulative inci-
dence of CRC: a starting from 
initial screening date according 
to sex. Competing risk death 
without CRC considered. Gray’s 
test p = 0.1473. b According to 
age group at screening. Com-
peting risk of death without 
CRC considered. Gray’s test 
p < 0.0001
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Fig. 3  a–c Cumulative inci-
dence of CRC: a according 
to screening findings. Polyps 
with adenomatous components 
combined into one group versus 
non-adenomatous polyps or 
inconspicuous findings. Gray’s 
test p = 0.0084. b According 
to polyp quantity. Gray’s test 
p = 0.0137. c According to 
the maximum polyp diameter. 
Gray’s test p < 0.0001
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on participants 50 years and older. This population is most 
at risk for CRC and therefore benefits the most from taking 
part in a screening colonoscopy program. A comparison of 
the CRC incidence to a matched population from the same 
region showed a significant drop in incidence among the 
screening target participants of 67% and 65% in men and 
women, respectively. The main predictive factor for CRC in 
univariate and multivariate analyses was age at screening, 
and for participants with polypectomy, a maximum diameter 
of over 10 mm was also indicative for CRC. These findings 
are concurrent to and supported by findings from a large 
systematic review by Brenner et al. published 2014 (Bren-
ner et al. 2014), as well as other more recent studies which 
reported a similar drop in CRC incidence (Pan et al. 2016; 
Ren et al. 2016; Click et al. 2018; Helsingen et al. 2019; 
Lee et al. 2020). The finding that polyp size is predictive for 
future CRC diagnosis further underscores the significance 
of this factor, especially considering its previously reported 
association to a less favorable histology and long-term risk 
of CRC (Pickhardt et al. 2018). The 10 mm cut-off rep-
resents an especially critical clinical factor, since a small 
percentage of these polyps contain cancerous cells (Lieber-
man 2009; Parsa et al. 2019). While a large study by Lee 
et al. or by He et al., as well as older studies found a similar 
association, the current study replicates these findings in a 
more recent, prospective cohort of participants not limited to 
Table 3  Multivariate fine-gray 
model of predictive factors for 
diagnosis of colorectal cancer 
during follow-up
The  modelStudy was constructed using all screening study participants older than 50 years at screening with-
out a diagnosis of CRC during screening. The  modelPolyp furthermore only considered participants over 
50 years at screening with polyp findings
a No event in the subgroup of participants with a maximum of  ≥ 5 polyps
Variable Groups Hazard ratio 95% CI p value
ModelStudy [n = 9654]
 Age at screening  < 0.0001
50–59 Ref. – –
60–69 1.862 1.004–3.454 0.0484
70–79 4.688 2.506–8.770  < 0.0001
 ≥ 80 2.349 0.530–10.404 0.2607
 Sex 0.4521
Female Ref. – –
Male 1.171 0.776–1.776 0.4521
 Polyp finding 0.0988
No finding Ref. – –
Adenomatous/mixed 1.564 1.017–2.403 0.0415
Non-adenomatous 0.947 0.447–2.007 0.8878
ModelPolyp [n = 3467]
 Age at screening  < 0.0001
50–59 Ref. –
60–69 2.796 0.821–9.521 0.1000
70–79 9.997 3.013–33.169 0.0002






Adenomatous 1.127 0.514–2.471 0.7660
Mixed 1.772 0.599–5.247 0.3016
 Polyp  Na 0.1030
1–2 Ref. –
3–4 1.717 0.896–3.289 0.1030
 Polyp mm 0.0002
< 5 Ref.
5–10 0.737 0.351–1.550 0.4215
 ≥ 10 3.110 1.538–6.291 0.0016
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Fig. 4  a–c Overall survival: a 
participants with CRC during 
follow-up stratified by sex. Log-
rank univariate p = 0.9821. b 
MCR population with CRC dur-
ing the same time period as the 
study stratified by sex. c Partici-
pants with CRC in comparison 
to five randomly drawn age- and 
sex-matched samples from the 
MCR population data
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sigmoidoscopy (Atkin et al. 1992; He et al. 2020; Lee et al. 
2020). Prognosis after CRC was also improved in a com-
parison to matched data samples from the MCR. Although 
survival in the prevalent CRC subgroup was similar to that 
of the cases during the follow-up period, this may largely 
be attributed to a younger age at diagnosis in the prevalent 
subgroup. An interesting finding was also the shift from the 
mainly left-sided CRC in the prevalent group to the slightly 
more frequent right-sided cases observed during follow-up. 
Similar results were found in previous studies (Brenner et al. 
2010). Reasons for this phenomenon may be that polyps on 
the right side tend to be harder to detect and removed dur-
ing colonoscopy due to their smaller size and more flattened 
appearance (Gupta et al. 2012). Other aspects such as bowel 
preparation may also play a role.
Looking at screening participation more women than men 
took part in the procedure. Women also had fewer positive 
findings, and polyps were mainly associated with a better 
prognosis compared to men. This sex-based difference in 
health-seeking behavior and colonoscopy findings are simi-
lar to results found in other studies with a similar objective 
(Gimeno Garcia 2012; Navarro et al. 2017). However, when 
taking age into consideration, no effect of sex remained.
The quality of the colonoscopy procedure is also fre-
quently discussed in playing an important role in screening 
efficacy. Fast proliferating de-novo tumors or interval can-
cers may be missed during a colonoscopy, the rate has been 
reported to lie between 2 and 6% (Samadder et al. 2014). In 
addition, an incomplete resection may also lead to a subse-
quent CRC; here, the reported rate from the CARE study 
was determined to lie at approximately 10% (Pohl et al. 
2013). The interval cases in this study cannot be identified 
and are therefore not classified as such; their impact can 
therefore not be determined. However, these are found in 
all screening-associated studies and irrespective of method-
ologies and compared to sporadic cases of CRC prognosis 
was nearly equivalent (Erichsen et al. 2013). According to a 
study by Ertem et al. in 2018, physicians performing colo-
noscopies will only fail to detect 2–4 interval CRCs during 
a 35-year practice (Ertem et al. 2018). This indicates that 
these missed tumors only have a minor impact on the overall 
number of cases.
Limiting the validity of these observed effects are the 
observational nature of this study and its limited strength in 
assessing causal association. Considering lead-time bias, the 
results above may falsely represent a better prognosis com-
pared to the general population who may or may not have 
undergone the same examination. Therefore, any improve-
ment in survival may be due to an earlier detection and gen-
eralizations should be made with caution (Facciorusso et al. 
2016). Also, an overdiagnosis bias may have selectively 
detected small and slower growing polyps rather than fast 
growing ones. However, which polyp will differentiate into 
an invasive carcinoma cannot be predicted and any observed 
effect can therefore not be fully attributed to the screening 
examination itself.
Aside from general limitations common to all screening 
studies, a main limitation in the study data is the lack of 
information on the reason for partaking in the examination. 
It may be assumed that not all participants can be consid-
ered asymptomatic screening patients, but were instead 
referred to the exam by their primary care physician based 
on reported symptoms. Therefore, the outcome of the analy-
ses may more likely reflect the effect of the polypectomy 
procedure studied for example by the National Polyp Study 
of 1993 by Winwar et al. (1993), which may be more suit-
able for direct comparison. Here, the authors also found a 
large reduction in CRC incidence following polypectomy 
during one or more colonoscopies over the study period. 
In addition, the interval for excluded cases of CRC after 
colonoscopy should have encompassed a longer time span 
to definitely rule out any missed carcinomas. Although only 
six cases occurred between 30 days and 6 months after the 
colonoscopy, it is unclear whether they developed de-novo 
or not.
Regardless of the evaluated methodology, colonoscopy 
examinations find, and a polypectomy removes precursor 
lesions, and both have a proven positive effect on CRC risk. 
Especially, adenomatous polyps are at an increased risk for 
developing into adenocarcinomas, slightly over half of pol-
yps found during a colonoscopy were of this type (Jass et al. 
2006). The reported percentages were similar to those found 
in the study data, and in univariate analysis significantly 
associated with subsequent CRC diagnosis. Comparison of 
adenomatous and mixed adenomatous/non-adenomatous 
polyps showed that an adenomatous component caused the 
polyp to carry a similar risk for CRC as those solely char-
acterized as adenomatous. Non-adenomatous polyps on the 
other hand are found less frequently and carry almost no 
malignancy risk (Harken and Moore 2018). In the study 
data, the participants with this type of polyp showed a risk 
for CRC comparable to those without any findings (Fig. 3a). 
However, polyp histology was not significant in multivari-
ate analysis, indicating that age-related changes to the colon 
microenvironment or microbiome may play a more influ-
ential role on carcinogenesis. Interestingly, the number 
of polyps was also only significant in univariate analysis; 
however, the subgroup with the highest number of polyps 
only represented a small number of participants and no cases 
of CRC. Potentially, a longer follow-up would increase the 
number of events in this category and a significant asso-
ciation would be found as expected. This factor is consid-
ered a main quality indicator for the colonoscopy procedure 
and was associated with subsequent CRC in other studies 
(Lieberman et al. 2000; Amano et al. 2018; Lee et al. 2018). 
If no polyps were found, a risk for CRC remained. In these 
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participants without any polyp findings, the reason for CRC 
development could be an underlying inflammatory disease, 
fast growing interval cancers, or the quality of the colonos-
copy procedure. These findings are similar to the published 
data by He et al. where advanced polyps also represented a 
higher risk in regard to CRC development, participants with-
out polyps also showed a lowered but inherent CRC risk (He 
et al. 2020). Regardless of polyp findings, participants with a 
successful colonoscopy procedure will likely seek follow-up 
screening and thus lower their risk for CRC in the long run.
No additional histopathological data on the removed pol-
yps were collected to further refine patient risk stratifica-
tion. Potentially, more detailed pathological classification of 
polyps could further refine patient subgroups and determine 
who would profit from more frequent surveillance exams.
In conclusion, colonoscopy with polypectomy is an effec-
tive screening tool in reducing the overall number of CRC 
in the general population. The incidence of CRC is expected 
to increase accordingly and with it the associated disease 
burden. A high uptake of preventive colonoscopy screening 
would therefore decrease the overall number of expected 
cases, especially those induced through the adenoma–car-
cinoma sequence. Fewer cases would mean alleviating some 
of the rising costs estimated to overwhelm the health care 
system in the next 10 years (Keum and Giovannucci 2019). 
A risk-based and adjusted screening interval for patients 
with larger polyp findings could be easily implemented and 
prove highly beneficial. The results of the study indicate 
that, in particular, younger participants may benefit espe-
cially, considering that larger polyps could be removed early 
in their growth and thereby lower the risk for CRC in the fol-
lowing years. Therefore, increasing participation and adher-
ence to screening programs should be a priority considering 
the expected increase in cases due to an increasingly aging 
population (Keum and Giovannucci 2019).
Supplementary Information The online version contains supplemen-
tary material available at https ://doi.org/10.1007/s0043 2-021-03532 -7.
Acknowledgements We thank all 11,842 study participants who took 
part in the study and submitted their baseline demographic data and 
screening results for this analysis. Our thanks also go to all 48 par-
ticipating gastroenterologists (see supplementary Table 2) who made 
the presented analyses possible. In particular, we would like to thank 
all MCR documentation staff who documented the screening data in 
addition to their routine work.
Author contributions Study conception and design were made by 
DH, GS, and JE. Data curation and statistical analysis were performed 
by KH, LB, AS, and MS. Data interpretation was performed by all 
authors. The first draft of the manuscript was written by KH and all 
authors commented on previous versions of the manuscript. All authors 
read and approved the final manuscript.
Funding Open Access funding enabled and organized by Projekt 
DEAL.
Availability of data and materials Study data can be made available 
for scientific purposes upon request and only after approval through 
study lead.
Code availability Analysis code can also be made available upon 
request.
Compliance with ethical standards 
Conflict of interest The authors declare no potential conflicts of inter-
est relevant to the manuscript.
Consent to participate A consent was obtained from all study par-
ticipants.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
Amano T, Nishida T, Shimakoshi H, Shimoda A, Osugi N, Sugimoto 
A, Takahashi K, Mukai K, Nakamatsu D, Matsubara T, Yamamoto 
M, Hayashi S, Nakajima S, Fukui K, Inada M (2018) Number of 
polyps detected is a useful indicator of quality of clinical colonos-
copy. Endosc Int Open 6(7):E878–E884
Atkin WS, Morson BC, Cuzick J (1992) Long-term risk of colorectal 
cancer after excision of rectosigmoid adenomas. N Engl J Med 
326(10):658–662
Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, North-
over JM, Parkin DM, Wardle J, Duffy SW, Cuzick J (2010) Once-
only flexible sigmoidoscopy screening in prevention of colo-
rectal cancer: a multicentre randomised controlled trial. Lancet 
375(9726):1624–1633
AWMF (2019) German Guideline Program in Oncology (German Can-
cer Society, German Cancer Aid, AWMF): S3-Guideline Colorec-
tal Cancer, long version 2.1.
Bray F, Colombet M, Mery L, Piñeros M, Znaor A, Zanetti R, Ferlay 
J, editors (2017) CHAPTER 7: age standardization. Cancer Inci-
dence in Five Continents, Vol. XI (electronic version). Interna-
tional Agency for Research on Cancer, Lyon
Brenner H, Hoffmeister M, Arndt V, Stegmaier C, Altenhofen L, Haug 
U (2010) Protection from right- and left-sided colorectal neo-
plasms after colonoscopy: population-based study. J Natl Cancer 
Inst 102(2):89–95
Brenner H, Stock C, Hoffmeister M (2014) Effect of screening sig-
moidoscopy and screening colonoscopy on colorectal cancer 
incidence and mortality: systematic review and meta-analysis 
of randomised controlled trials and observational studies. BMJ 
348:g2467
Journal of Cancer Research and Clinical Oncology 
1 3
Click B, Pinsky PF, Hickey T, Doroudi M, Schoen RE (2018) Associa-
tion of colonoscopy adenoma findings with long-term colorectal 
cancer incidence. JAMA 319(19):2021–2031
Erichsen R, Baron JA, Stoffel EM, Laurberg S, Sandler RS, Sorensen 
HT (2013) Characteristics and survival of interval and sporadic 
colorectal cancer patients: a nationwide population-based cohort 
study. Am J Gastroenterol 108(8):1332–1340
Ertem FU, Ladabaum U, Mehrotra A, Tehranian S, Shi Z, Saul M, 
Morris M, Crockett SD, Schoen RE (2018) Incidence of interval 
colorectal cancer attributable to an endoscopist in clinical prac-
tice. Gastrointest Endosc 88(4):705–711.e701
Facciorusso A, Ferrusquia J, Muscatiello N (2016) Lead time bias in 
estimating survival outcomes. Gut 65(3):538–539
Fine JP, Gray RJ (1999) A proportional hazards model for the subdis-
tribution of a competing risk. J Am Stat Assoc 94(446):496–509
Gimeno Garcia AZ (2012) Factors influencing colorectal cancer 
screening participation. Gastroenterol Res Pract 2012:483417
Gupta S, Balasubramanian BA, Fu T, Genta RM, Rockey DC, Lash R 
(2012) Polyps with advanced neoplasia are smaller in the right 
than in the left colon: implications for colorectal cancer screening. 
Clin Gastroenterol Hepatol 10(12):1395–1401.e1392
Harken AH, Moore EE (2018) Abernathy’s surgical secrets.
He X, Hang D, Wu K, Nayor J, Drew DA, Giovannucci EL, Ogino S, 
Chan AT, Song M (2020) Long-term risk of colorectal cancer 
after removal of conventional adenomas and serrated polyps. Gas-
troenterology 158(4):852–861.e854
Helsingen LM, Vandvik PO, Jodal HC, Agoritsas T, Lytvyn L, Ander-
son JC, Auer R, Murphy SB, Almadi MA, Corley DA, Quinlan C, 
Fuchs JM, McKinnon A, Qaseem A, Heen AF, Siemieniuk RAC, 
Kalager M, Usher-Smith JA, Lansdorp-Vogelaar I, Bretthauer M, 
Guyatt G (2019) Colorectal cancer screening with faecal immu-
nochemical testing, sigmoidoscopy or colonoscopy: a clinical 
practice guideline. BMJ 367:l5515
Issa IA, Noureddine M (2017) Colorectal cancer screening: an 
updated review of the available options. World J Gastroenterol 
23(28):5086–5096
Jass JR, Baker K, Zlobec I, Higuchi T, Barker M, Buchanan D, Young 
J (2006) Advanced colorectal polyps with the molecular and 
morphological features of serrated polyps and adenomas: con-
cept of a “fusion” pathway to colorectal cancer. Histopathology 
49(2):121–131
Kalbfleisch JD, Prentice RL (2011) The statistical analysis of failure 
time data.
Kaminski MF, Regula J, Kraszewska E, Polkowski M, Wojciechowska 
U, Didkowska J, Zwierko M, Rupinski M, Nowacki MP, Butruk E 
(2010) Quality indicators for colonoscopy and the risk of interval 
cancer. N Engl J Med 362(19):1795–1803
Keum N, Giovannucci E (2019) Global burden of colorectal cancer: 
emerging trends, risk factors and prevention strategies. Nat Rev 
Gastroenterol Hepatol 16(12):713–732
Lee J, Seo JW, Sim HC, Choi JH, Heo NY, Park J, Park SH, Moon 
YS, Kim TO (2018) Predictors of high-risk adenoma occurrence 
at surveillance colonoscopy in patients who undergo colorectal 
adenoma removal. Dig Dis 36(5):354–361
Lee JK, Jensen CD, Levin TR, Doubeni CA, Zauber AG, Chubak J, 
Kamineni AS, Schottinger JE, Ghai NR, Udaltsova N, Zhao WK, 
Fireman BH, Quesenberry CP, Orav EJ, Skinner CS, Halm EA, 
Corley DA (2020) Long-term risk of colorectal cancer and related 
death after adenoma removal in a large, community-based popula-
tion. Gastroenterology 158(4):884–894.e885
Lieberman DA (2009) Clinical practice. Screening for colorectal can-
cer. N Engl J Med 361(12):1179–1187
Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec 
G (2000) Use of colonoscopy to screen asymptomatic adults for 
colorectal cancer. Veterans Affairs Cooperative Study Group 380. 
N Engl J Med 343(3):162–168
“Munich Cancer Registry (MCR)” (2019) https ://www.tumor regis ter-
muenc hen.de/en/index .php. Accessed 09 Dec 2019
Navarro M, Nicolas A, Ferrandez A, Lanas A (2017) Colorectal cancer 
population screening programs worldwide in 2016: an update. 
World J Gastroenterol 23(20):3632–3642
Niedermaier T, Weigl K, Hoffmeister M, Brenner H (2018) Flex-
ible sigmoidoscopy in colorectal cancer screening: implications 
of different colonoscopy referral strategies. Eur J Epidemiol 
33(5):473–484
Pan J, Xin L, Ma YF, Hu LH, Li ZS (2016) Colonoscopy reduces 
colorectal cancer incidence and mortality in patients with 
non-malignant findings: a meta-analysis. Am J Gastroenterol 
111(3):355–365
Parsa N, Ponugoti P, Broadley H, Garcia J, Rex DK (2019) Risk of 
cancer in 10–19 mm endoscopically detected colorectal lesions. 
Endoscopy 51(5):452–457
Pickhardt PJ, Pooler BD, Kim DH, Hassan C, Matkowskyj KA, Halberg 
RB (2018) The natural history of colorectal polyps: overview of 
predictive static and dynamic features. Gastroenterol Clin N Am 
47(3):515–536
Pohl H, Srivastava A, Bensen SP, Anderson P, Rothstein RI, Gordon 
SR, Levy LC, Toor A, Mackenzie TA, Rosch T, Robertson DJ 
(2013) Incomplete polyp resection during colonoscopy-results of 
the complete adenoma resection (CARE) study. Gastroenterology 
144(1):74–80.e71
Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas A, 
Andreu M, Carballo F, Morillas JD, Hernandez C, Jover R, 
Montalvo I, Arenas J, Laredo E, Hernandez V, Iglesias F, Cid 
E, Zubizarreta R, Sala T, Ponce M, Andres M, Teruel G, Peris 
A, Roncales MP, Polo-Tomas M, Bessa X, Ferrer-Armengou O, 
Grau J, Serradesanferm A, Ono A, Cruzado J, Perez-Riquelme F, 
Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho 
G, Diaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, 
Gonzalez-Navarro A, Investigators CS (2012) Colonoscopy versus 
fecal immunochemical testing in colorectal-cancer screening. N 
Engl J Med 366(8):697–706
Ren J, Kirkness CS, Kim M, Asche CV, Puli S (2016) Long-term risk 
of colorectal cancer by gender after positive colonoscopy: popu-
lation-based cohort study. Curr Med Res Opin 32(8):1367–1374
Samadder NJ, Curtin K, Tuohy TM, Pappas L, Boucher K, Provenzale 
D, Rowe KG, Mineau GP, Smith K, Pimentel R, Kirchhoff AC, 
Burt RW (2014) Characteristics of missed or interval colorectal 
cancer and patient survival: a population-based study. Gastroen-
terology 146(4):950–960
Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Lai-
yemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, 
Fouad MN, Isaacs C, Johnson CC, Reding DJ, O’Brien B, Carrick 
DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, 
Miller AB, Gohagan JK, Prorok PC, Berg CD, P. P. Team (2012) 
Colorectal-cancer incidence and mortality with screening flexible 
sigmoidoscopy. N Engl J Med 366(25):2345–2357
Starker A, Buttmann-Schweiger N, Krause L, Barnes B, Kraywinkel 
K, Holmberg C (2018) Krebsfrüherkennungsuntersuchungen in 
Deutschland: Angebot und Inanspruchnahme. Bundesgesund-
heitsbl Bundesgesundheitsblatt - Gesundheitsforschung - Gesund-
heitsschutz 61(12):1491–1499
Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH 
(1999) Population-based surveillance by colonoscopy: effect on 
the incidence of colorectal cancer. Telemark Polyp Study I. Scand 
J Gastroenterol 34(4):414–420
Vuik FE, Nieuwenburg SA, Bardou M, Lansdorp-Vogelaar I, Dinis-
Ribeiro M, Bento MJ, Zadnik V, Pellise M, Esteban L, Kaminski 
MF, Suchanek S, Ngo O, Majek O, Leja M, Kuipers EJ, Spaander 
MC (2019) Increasing incidence of colorectal cancer in young 
adults in Europe over the last 25 years. Gut 68(10):1820–1826
 Journal of Cancer Research and Clinical Oncology
1 3
Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, Stern-
berg SS, Waye JD, Schapiro M, Bond JH, Panish JF et al (1993) 
Prevention of colorectal cancer by colonoscopic polypec-
tomy. The National Polyp Study Workgroup. N Engl J Med 
329(27):1977–1981
Zauber AG, Winawer SJ, O’Brien MJ, Lansdorp-Vogelaar I, van Bal-
legooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish 
JF, Stewart ET, Waye JD (2012) Colonoscopic polypectomy and 
long-term prevention of colorectal-cancer deaths. N Engl J Med 
366(8):687–696
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
